Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia.

Cross NCP, Hoade Y, Tapper WJ, Carreno-Tarragona G, Fanelli T, Jawhar M, Naumann N, Pieniak I, Lübke J, Ali S, Bhuller K, Burgstaller S, Cargo C, Cavenagh J, Duncombe AS, Das-Gupta E, Evans P, Forsyth P, George P, Grimley C, Jack F, Munro L, Mehra V, Patel K, Rismani A, Sciuccati G, Thomas-Dewing R, Thornton P, Virchis A, Watt S, Wallis L, Whiteway A, Zegocki K, Bain BJ, Reiter A, Chase A.

Leukemia. 2019 Feb;33(2):415-425. doi: 10.1038/s41375-018-0342-3. Epub 2018 Dec 20.

2.

Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic ERCC6L2 variants.

Tummala H, Dokal AD, Walne A, Ellison A, Cardoso S, Amirthasigamanipillai S, Kirwan M, Browne I, Sidhu JK, Rajeeve V, Rio-Machin A, Seraihi AA, Duncombe AS, Jenner M, Smith OP, Enright H, Norton A, Aksu T, Özbek NY, Pontikos N, Cutillas P, Dokal I, Vulliamy T.

Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):7777-7782. doi: 10.1073/pnas.1803275115. Epub 2018 Jul 9.

3.

The MOSAICC study: Assessing feasibility for biological sample collection in epidemiology studies and comparison of DNA yields from saliva and whole blood samples.

James G, McMullin MF, Duncombe AS, Clarke M, Anderson LA.

Ann Hum Genet. 2018 Mar;82(2):114-118. doi: 10.1111/ahg.12227. Epub 2017 Oct 27.

PMID:
29076129
4.

Results of the randomized phase IIB ARCTIC trial of low-dose rituximab in previously untreated CLL.

Howard DR, Munir T, McParland L, Rawstron AC, Milligan D, Schuh A, Hockaday A, Allsup DJ, Marshall S, Duncombe AS, O'Dwyer JL, Smith AF, Longo R, Varghese A, Hillmen P.

Leukemia. 2017 Nov;31(11):2416-2425. doi: 10.1038/leu.2017.96. Epub 2017 Mar 24.

5.

Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls.

Anderson LA, James G, Duncombe AS, Mesa R, Scherber R, Dueck AC, de Vocht F, Clarke M, McMullin MF.

Am J Hematol. 2015 Oct;90(10):864-70. doi: 10.1002/ajh.24098. Epub 2015 Sep 10.

6.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms.

Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC.

Nat Commun. 2015 Apr 7;6:6691. doi: 10.1038/ncomms7691.

7.

Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study.

McMullin MF, James G, Duncombe AS, de Vocht F, Fritschi L, Clarke M, Anderson LA.

Exp Hematol Oncol. 2016 May 26;5:14. doi: 10.1186/s40164-016-0043-4. eCollection 2015.

8.

Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK.

Krysov S, Steele AJ, Coelho V, Linley A, Sanchez Hidalgo M, Carter M, Potter KN, Kennedy B, Duncombe AS, Ashton-Key M, Forconi F, Stevenson FK, Packham G.

Blood. 2014 Nov 13;124(20):3101-9. doi: 10.1182/blood-2014-04-567198. Epub 2014 Aug 28.

9.

How common are myeloproliferative neoplasms? A systematic review and meta-analysis.

Titmarsh GJ, Duncombe AS, McMullin MF, O'Rorke M, Mesa R, De Vocht F, Horan S, Fritschi L, Clarke M, Anderson LA.

Am J Hematol. 2014 Jun;89(6):581-7. Review. Erratum in: Am J Hematol. 2015 Sep;90(9):850.

10.

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012.

Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN.

Br J Haematol. 2014 Nov;167(3):418-20. doi: 10.1111/bjh.12985. Epub 2014 Jun 25. No abstract available.

PMID:
24961987
11.

Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia.

Paterson A, Mockridge CI, Adams JE, Krysov S, Potter KN, Duncombe AS, Cook SJ, Stevenson FK, Packham G.

Blood. 2012 Feb 16;119(7):1726-36. doi: 10.1182/blood-2011-07-367417. Epub 2011 Dec 7.

PMID:
22160382
12.

Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms.

Anderson LA, Duncombe AS, Hughes M, Mills ME, Wilson JC, McMullin MF.

Am J Hematol. 2012 Feb;87(2):175-82. doi: 10.1002/ajh.22212. Epub 2011 Nov 11. Review.

13.

Necrobiotic xanthogranuloma occurring in an eyelid scar.

Rayner SA, Duncombe AS, Keefe M, Theaker J, Manners RM.

Orbit. 2008;27(3):191-4. doi: 10.1080/01676830701804057.

PMID:
18569827
14.

Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia.

Potter KN, Mockridge CI, Neville L, Wheatley I, Schenk M, Orchard J, Duncombe AS, Packham G, Stevenson FK.

Clin Cancer Res. 2006 Mar 15;12(6):1672-9.

15.

X-linked sideroblastic anaemia with ataxia: another mitochondrial disease?

Hellier KD, Hatchwell E, Duncombe AS, Kew J, Hammans SR.

J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):65-9.

16.

Automated immature reticulocyte counts are early markers of engraftment following autologous PBSC transplantation in patients with lymphoma.

George P, Wyre RM, Bruty SJ, Sweetenham JW, Duncombe AS.

J Hematother Stem Cell Res. 2000 Apr;9(2):219-23.

PMID:
10813535
17.

Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy.

Bakri FE, Pallett A, Smith AG, Duncombe AS.

J Antimicrob Chemother. 2000 Mar;45(3):383-6.

PMID:
10702563
18.

Ototoxicity induced by once-daily gentamicin.

El Bakri F, Pallett A, Smith AG, Duncombe AS.

Lancet. 1998 May 9;351(9113):1407-8. No abstract available.

PMID:
9593419
19.

Acute leukaemia in Jehovah's Witnesses.

Cullis JO, Duncombe AS, Dudley JM, Lumley HS, Apperley JF, Smith AG.

Br J Haematol. 1998 Mar;100(4):664-8.

PMID:
9531331
20.

Granulocyte colony-stimulating factor. A new application for cytomegalovirus-induced neutropenia in cardiac allograft recipients.

Patel HD, Anderson JR, Duncombe AS, Carrington D, Murday A.

Transplantation. 1994 Oct 15;58(7):863-7. No abstract available.

PMID:
7940727
21.

Bone marrow transplant recipients have defective MHC-unrestricted cytotoxic responses against cytomegalovirus in comparison with Epstein-Barr virus: the importance of target cell expression of lymphocyte function-associated antigen 1 (LFA1).

Duncombe AS, Grundy JE, Oblakowski P, Prentice HG, Gottlieb DJ, Roy DM, Reittie JE, Bello-Fernandez C, Hoffbrand AV, Brenner MK.

Blood. 1992 Jun 1;79(11):3059-66.

PMID:
1316791
22.

Interleukin 2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation.

Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Mehta AB, Hoffbrand AV, Brenner MK.

Br J Haematol. 1991 Feb;77(2):237-44.

PMID:
2004026
23.

Interleukin-2 infusion after autologous bone marrow transplantation enhances hemopoietic regeneration.

Heslop HE, Duncombe AS, Reittie JE, Bello-Fernandez C, Gottlieb DJ, Prentice HG, Hoffbrand AV, Brenner MK.

Transplant Proc. 1991 Feb;23(1 Pt 2):1704-5. No abstract available.

PMID:
1989334
24.

IL-4 acts as a homeostatic regulator of IL-2-induced TNF and IFN-gamma.

Bello-Fernandez C, Oblakowski P, Meager A, Duncombe AS, Rill DM, Hoffbrand AV, Brenner MK.

Immunology. 1991 Feb;72(2):161-6. Erratum in: Immunology 1991 May;73(1):128.

25.

IL2 activated killer cells may contribute to cytomegalovirus induced marrow hypoplasia after bone marrow transplantation.

Duncombe AS, Grundy JE, Prentice HG, Brenner MK.

Bone Marrow Transplant. 1991 Feb;7(2):81-7.

PMID:
1646663
26.

CMV-induced augmentation of GVL effect may be mediated by cytokines.

Duncombe AS, Grundy JE, Prentice HG, Brenner MK.

Bone Marrow Transplant. 1991 Jan;7(1):69. No abstract available.

PMID:
1646052
27.

Immunity against Pseudomonas aeruginosa adoptively transferred to bone marrow transplant recipients.

Gottlieb DJ, Cryz SJ Jr, Furer E, Que JU, Prentice HG, Duncombe AS, Brenner MK.

Blood. 1990 Dec 15;76(12):2470-5.

PMID:
2124933
28.

Gamma-interferon and tumor necrosis factor production after bone marrow transplantation is augmented by exposure to marrow fibroblasts infected with cytomegalovirus.

Duncombe AS, Meager A, Prentice HG, Grundy JE, Heslop HE, Hoffbrand AV, Brenner MK.

Blood. 1990 Sep 1;76(5):1046-53.

PMID:
2168224
29.

Requirements for the adoptive transfer of antibody responses to a priming antigen in man.

Wimperis JZ, Gottlieb D, Duncombe AS, Heslop HE, Prentice HG, Brenner MK.

J Immunol. 1990 Jan 15;144(2):541-7.

PMID:
2136894
30.

Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia.

Duncombe AS, Heslop HE, Turner M, Meager A, Priest R, Exley T, Brenner MK.

J Immunol. 1989 Dec 1;143(11):3828-34.

PMID:
2584719
31.

Intravenous immunoglobulin therapy in thrombocytopenic infectious mononucleosis.

Duncombe AS, Amos RJ, Metcalfe P, Pearson TC.

Clin Lab Haematol. 1989;11(1):11-5.

PMID:
2706900
32.

Is circulating tumor necrosis factor bioactive?

Duncombe AS, Brenner MK.

N Engl J Med. 1988 Nov 3;319(18):1227-8. No abstract available.

PMID:
3173463
33.

Bioactivity and immunoreactivity of tumour necrosis factor in cancer patients.

Duncombe AS, Gottlieb DJ, Bianchi A, Brenner MK.

Lancet. 1988 Jan 30;1(8579):248. No abstract available.

PMID:
2893076
34.

Compression of the optic chiasm due to a lymphoreticular malignancy.

Howard RS, Duncombe AS, Owens C, Graham E.

Postgrad Med J. 1987 Dec;63(746):1091-3.

35.

1,25 Dihydroxy-vitamin D3 (1,25 (OH)2 vit D3) in the treatment of idiopathic myelofibrosis.

Duncombe AS, Pearson TC, Nunan TO, Miller A, McCarthy DM.

Br J Haematol. 1987 Aug;66(4):579-80. No abstract available.

PMID:
3663514
36.

C-reactive protein and cytosine arabinoside.

Dudley JM, Duncombe AS, Slater NG, Sturgess I.

Br J Haematol. 1987 Jun;66(2):280-1. No abstract available.

PMID:
3475116
37.

Monosomy 7 and Ph-positive acute lymphoblastic leukaemia: cytogenetic and molecular aspects.

Eridani S, Gorman P, Sheer D, Duncombe AS, Glass UH, Shivji MK.

Leuk Res. 1987;11(11):965-9.

PMID:
3480400
38.

Lupus-type coagulation inhibitor in hairy cell leukaemia and resolution with splenectomy.

Duncombe AS, Dalton RG, Savidge GF.

Br J Haematol. 1987 Jan;65(1):120-1. No abstract available.

PMID:
3101730
39.

HTLV-III related illness and Christmas disease.

Duncombe AS, Savidge GF, Craske J.

Lancet. 1986 Feb 22;1(8478):447-8. No abstract available.

PMID:
2868367
41.

Spinal subarachnoid haemorrhage presenting as spinal block without meningism.

Duncombe AS, Kennedy PG.

Postgrad Med J. 1985 Nov;61(721):991-3.

42.

Methysergide in progressive supranuclear palsy.

Duncombe AS, Lees AJ.

Neurology. 1985 Jun;35(6):936-7. No abstract available.

PMID:
4000498

Supplemental Content

Loading ...
Support Center